Nanocarrier Drug Delivery Systems Research Articles

Smart Peptide/Au Nano-carriers for Drug Delivery Systems: Synthesis and Characterization, Interactions with Calf Thymus DNA, and In Vitro Cytotoxicity Studies

Smart Peptide/Au Nano-carriers for Drug Delivery Systems: Synthesis and Characterization, Interactions with Calf Thymus DNA, and In Vitro Cytotoxicity Studies

Experimental and theoretical approach on green synthesized zinc oxide nanoparticles from combined leaf extracts of Catharanthus roseus and Morinda Citrifolia for invitro anti-cancer studies

Recently, the development of green synthesized nanoparticles with anticancer studies has been an emerging field in the pharmaceutical industry. Herein reported the synthesis of zinc oxide nanoparticles from combined leaf extracts ofCatharanthus roseus (CR) andMorinda Citrifolia(MC) and its interaction pattern with target cancer protein-synthesizing DNA fragments. Previously reported structures of 9 biologically activated phytoconstituents ofCatharanthus roseusandMorinda Citrifolia were collected and blended with Zinc oxide and to identify the best stable complex using the χ value and Emix value with the help of the material studio software. Also, the adsorption location of the zinc atom on the position of the phytoconstituents was analysed to confirm the capping phytoconstituents. Finally, the best stable complex was docked with a human parallel stranded 7-mer g-quadruplex complex to know the inhibition ability. The obtained algorithm results indicated that the biophore Quercetin-3-O-alpha-L-rhamnopyranoside capping on the zinc ion well through the π – cationic and metal acceptor interaction with lowest Emix value and χ value of 12.04616and 20.34180 respectively. The docking results of this complex with 6KN4 DNA formed multiple interactions such as rhamnopyranoside ring with guanine nucleotide base and chromene ring hydrophobic interaction through the zinc ion compared to the standard drug. The docking energy of the system after analysis was found to be −128.997 kcal/mol and this indicates that the zinc capped Quercetin-3-O-alpha-L-rhamnopyranoside the complex will inhibit the 6KN4 irreversibly compare to standard Doxorubicin. To confirm the computational analysis, green synthesized Zinc Oxide nanoparticles were also subjected to invitro anticancer studies against MCF −7 cell lines. The results from experimental and theoretical calculations give an insight into the development of an efficient eco-friendly nanocarrier for drug delivery systems.

Biological fate and interaction with cytochromes P450 of the nanocarrier material, d-α-tocopheryl polyethylene glycol 1000 succinate

d-α-Tocopheryl polyethylene glycol 1000 succinate (TPGS, also known as vitamin E-TPGS) is a biodegradable amphiphilic polymer prepared by esterification of vitamin E with polyethylene glycol (PEG) 1000. It is approved by the US Food and Drug Administration (FDA) and has found wide application in nanocarrier drug delivery systems (NDDS). Fully characterizing the in vivo fate and pharmacokinetic behavior of TPGS is important to promote the further development of TPGS-based NDDS. However, to date, a bioassay for the simultaneous quantitation of TPGS and its metabolite, PEG1000, has not been reported. In the present study, we developed such an innovative bioassay and used it to investigate the pharmacokinetics, tissue distribution and excretion of TPGS and PEG1000 in rat after oral and intravenous dosing. In addition, we evaluated the interaction of TPGS with cytochromes P450 (CYP450s) in human liver microsomes. The results show that TPGS is poorly absorbed after oral administration with very low bioavailability and that, after intravenous administration, TPGS and PEG1000 are mainly distributed to the spleen, liver, lung and kidney before both being slowly eliminated in urine and feces as PEG1000. In vitro studies show the inhibition of human CYP450 enzymes by TPGS is limited to a weak inhibition of CYP3A4. Overall, our results provide a clear picture of the in vivo fate of TPGS which will be useful in evaluating the safety of TPGS-based NDDS in clinical use and in promoting their further development.

The In Vivo Pharmacokinetics of Block Copolymers Containing Polyethylene Glycol Used in Nanocarrier Drug Delivery Systems.

Polyethylene glycol (PEG) is one of the most commonly used synthetic macromolecular polymers for modifying small molecule drugs, peptides, proteins, or nanodrug delivery systems to improve their water solubility, biocompatibility, and stability. Block copolymers containing PEG have been widely used in nanodrug delivery systems such as solid lipid nanoparticles, polymeric nanoparticles, polymeric micelles, and liposomes. To date, although numerous PEGylated nanodrug delivery systems have been developed, only a few have been approved for clinical application. Poor safety and effectivity are important reasons for the high failure rate of nanodrug delivery system clinical trials. These factors are not only related to the loaded drugs and released drugs but are also related to the nanocarriers. Therefore, investigating the in vivo spatiotemporal fate of block copolymers containing PEG used in nanodrug delivery systems is necessary and important for evaluating their safety, efficacy, and toxicity. In this article, we will review the information that has been reported about the absorption, distribution, metabolism, and excretion of block copolymers containing PEG. We believe this review is helpful to understand the biologic fate of block copolymers containing PEG.This review describes pharmacokinetic study of block copolymers containing polyethylene glycol. The main focus of this paper is the in vivo fate of these polyethylene glycol-related copolymers after their release from nanocarriers. This review is helpful for understanding of the in vivo fate of block copolymers containing polyethylene glycol used in nanocarrier drug delivery systems.

HIGH-THROUGHPUT SCREENING AND DYNAMIC STUDIES OF SELECTED COMPOUNDS AGAINST SARS-COV-2

Objective: This study was aimed to analyze the inhibitory effect of the drugs used in nanocarrier as well as nanoparticles formulation based drug delivery system selected from PubChem database literature against 3CLpro (3C-like protease) receptor of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) by implementing several in silico analysis techniques. Methods: This paper detailed a molecular docking-based virtual screening of 5240 compounds previously utilized in nanoparticle and nanocarrier drug delivery systems utilizing AutoDock Vina software on 3CL protease to discover potential inhibitors using a molecular docking technique. Results: According to the results of the screening, the top two compounds, PubChem Id 58823276 and PubChem Id 60838 exhibited a high affinity for the 3CL protease binding region. Their binding affinities were-9.6 and-8.5 kJ/mol, indicating that they were tightly bound to the target receptor, respectively. These results outperformed those obtained using the co-crystallized native ligand, which exhibited a binding affinity of-7.4 kJ/mol. PubChem Id 60838, the main hit compound in terms of both binding affinity and ADMET analysis, displayed substantial deformability after MD simulation. As a result of the VS and molecular docking techniques, novel 3CL protease inhibitors from the PubChem database were discovered using the Lipinski rule of five and functional molecular contacts with the target protein, as evidenced by the findings of this work. Conclusion: The findings suggest that the compounds discovered may represent attractive opportunities for the development of COVID-19 3CLpro inhibitors and that they need further evaluation and investigation.

Fabrication of hydrolase responsive diglycerol based Gemini amphiphiles for dermal drug delivery applications.

Since biocatalysts manoeuvre most of the physiological activities in living organisms and exhibit extreme selectivity and specificity, their use to trigger physicochemical change in polymeric architectures has been successfully used for targeted drug delivery. Our major interest is to develop lipase responsive nanoscale delivery systems from bio-compatible and biodegradable building blocks. Herein, we report the synthesis of four novel non-ionic Gemini amphiphiles using a chemo-enzymatic approach. A symmetrical diglycerol has been used as a core that is functionalised with alkyl chains for the creation of a hydrophobic cavity, and for aqueous solubility (polyethylene glycol) monomethyl ether (mPEG) is incorporated. Such systems can exhibit a varied self-assembly behaviour leading to the observance of different morphological structures. The aggregation behaviour of the synthesised nanocarrier was studied by dynamic light scattering (DLS) and critical aggregation concentration (CAC) measurements. The nanotransport potential of amphiphiles was investigated for hydrophobic guest molecules, i.e. Nile red, nimodipine and curcumin. Cytotoxicity of the amphiphiles was studied using HeLa and MCF7 cell lines at different concentrations, i.e. 0.05, 0.1, and 0.5 mg mL−1. All nanocarriers were found to be non-cytotoxic up to a concentration of 0.1 mg mL−1. Confocal laser scanning microscopy (cLSM) study suggested the uptake of encapsulated dye in the cytosol of the cancer cells within 4 h, thus implying that amphiphilic systems can efficiently transport hydrophobic drug molecules into cells. The biomedical application of the synthesised Gemini amphiphiles was also investigated for dermal drug delivery. In addition, the enzyme-mediated release study was performed that demonstrated 90% of the dye is released within three days. All these results supported the capability of nanocarriers in drug delivery systems.

Perspectives of metal-organic framework nanosystem to overcome tumor drug resistance.

Cancer is one of the most harmful diseases in the world, which causes huge numbers of deaths every year. Many drugs have been developed to treat tumors. However, drug resistance usually develops after a period of time, which greatly weakens the therapeutic effect. Tumor drug resistance is characterized by blocking the action of anticancer drugs, resisting apoptosis and DNA repair, and evading immune recognition. To tackle tumor drug resistance, many engineered drug delivery systems (DDS) have been developed. Metal-organic frameworks (MOFs) are one kind of emerging and promising nanocarriers for DDS with high surface area and abundant active sites that make the functionalization simpler and more efficient. These features enable MOFs to achieve advantages easily towards other materials. In this review, we highlight the main mechanisms of tumor drug resistance and the characteristics of MOFs. The applications and opportunities of MOF-based DDS to overcome tumor drug resistance are also discussed, shedding light on the future development of MOFs to address tumor drug resistance.

Control of Specific/Nonspecific Protein Adsorption: Functionalization of Polyelectrolyte Multilayer Films as a Potential Coating for Biosensors.

Control of nonspecific/specific protein adsorption is the main goal in the design of novel biomaterials, implants, drug delivery systems, and sensors. The specific functionalization of biomaterials can be achieved by proper surface modification. One of the important strategies is covering the materials with functional coatings. Therefore, our work aimed to functionalize multilayer coating to control nonspecific/specific protein adsorption. The polyelectrolyte coating was formed using a layer-by-layer technique (LbL) with biocompatible polyelectrolytes poly-L-lysine hydrobromide (PLL) and poly-L-glutamic acid (PGA). Nonspecific protein adsorption was minimized/eliminated by pegylation of multilayer films, which was achieved by adsorption of pegylated polycations (PLL-g-PEG). The influence of poly (ethylene glycol) chain length on eliminating nonspecific protein adsorption was confirmed. Moreover, to achieve specific protein adsorption, the multilayer film was also functionalized by immobilization of antibodies via a streptavidin bridge. The functional coatings were tested, and the adsorption of the following proteins confirmed the ability to control nonspecific/specific adsorption: human serum albumin (HSA), fibrinogen (FIB), fetal bovine serum (FBS), carcinoembryonic antigen human (CEA) monitored by quartz crystal microbalance with dissipation (QCM-D). AFM imaging of unmodified and modified multilayer surfaces was also performed. Functional multilayer films are believed to have the potential as a novel platform for biotechnological applications, such as biosensors and nanocarriers for drug delivery systems.

Recent advances in PLGA based nanocarriers for drug delivery system: a state of the art review

The biomolecules in the clinical use being delivered by the conventional mode of delivery often exhibit poor affinity. So, there is a need for a nanomedicine-based approach that could propose a promising solution to the problems coupled with conventional drug delivery. In this context, the application of Poly (lactic-co-glycolic acid) (PLGA) nanocarriers in drug delivery is a promising approach to achieve good biodistribution and absorption of therapeutics to the diseased site with a reduction in toxicity. This review covers various approaches to synthesize PLGA polymer, its physiochemical, biological assets, functionalized carriers for the advancement of nano delivery to the target site, and current modern approaches having the potential to deliver PLGA-based nanomedicines against a variety of diseases.

Enhanced Stability and Bioactivity of Natural Anticancer Topoisomerase I Inhibitors through Cyclodextrin Complexation.

The use of cyclodextrins as drug nano-carrier systems for drug delivery is gaining importance in the pharmaceutical industry due to the interesting pharmacokinetic properties of the resulting inclusion complexes. In the present work, complexes of the anti-cancer alkaloids camptothecin and luotonin A have been prepared with β-cyclodextrin and hydroxypropyl-β-cyclodextrin. These cyclodextrin complexes were characterized by nuclear magnetic resonance spectroscopy (NMR). The variations in the 1H-NMR and 13C-NMR chemical shifts allowed to establish the inclusion modes of the compounds into the cyclodextrin cavities, which were supported by docking and molecular dynamics studies. The efficiency of the complexation was quantified by UV-Vis spectrophotometry and spectrofluorimetry, which showed that the protonation equilibria of camptothecin and luotonin A were drastically hampered upon formation of the inclusion complexes. The stabilization of camptothecin towards hydrolysis inside the cyclodextrin cavity was verified by the quantitation of the active lactone form by reverse phase liquid chromatography fluorimetric detection, both in basic conditions and in the presence of serum albumin. The antitumor activity of luotonin A and camptothecin complexes were studied in several cancer cell lines (breast, lung, hepatic carcinoma, ovarian carcinoma and human neuroblastoma) and an enhanced activity was found compared to the free alkaloids, particularly in the case of hydroxypropyl-β-cyclodextrin derivatives. This result shows that the cyclodextrin inclusion strategy has much potential towards reaching the goal of employing luotonin A or its analogues as stable analogues of camptothecin.

Smart stimuli-responsive nanocarriers for the cancer therapy – nanomedicine

Abstract Nanomedicine is ongoing current research in the applications of nanotechnology for cancer therapy. Simply from a technology perspective, this field of research has an enormous broadening and success to date. Recently, nanomedicine has also made inroads in the treatment of cancer. Stimuli-responsive nanoparticles are an emerging field of research because its targeting capacity is of great interest in the treatment of cancer. The responsive nanoparticles are efficient in encountering different internal biological stimuli (acidic, pH, redox, and enzyme) and external stimuli (temperature, ultrasounds, magnetic field, and light), which are used as smart nanocarriers for delivery of the chemotherapeutic and imaging agents for cancer therapy. In-depth, the responsive nanocarrier that responds to the biological cues is of pronounced interest due to its capability to provide a controlled release profile at the tumor-specific site. The outlook of this review focuses on the stimuli-responsive nanocarrier drug delivery systems in sequence to address the biological challenges that need to be evaluated to overcome conventional cancer therapy.

Extracellular Vesicles as Drug Delivery System for Treatment of Neurodegenerative Disorders: Optimization of the Cell Source.

Extracellular vesicles (EVs) represent a next generation drug delivery system that combines nanoparticle size with extraordinary ability to cross biological barriers, reduced immunogenicity, and low offsite toxicity profiles. A successful application of this natural way of delivering biological compounds requires deep understanding EVs intrinsic properties inherited from their parent cells. Herein, we evaluated EVs released by cells of different origin, with respect to drug delivery to the brain for treatment of neurodegenerative disorders. The morphology, size, and zeta potential of EVs secreted by primary macrophages (mEVs), neurons (nEVs), and astrocytes (aEVs) were examined by nanoparticle NTA, DLS, cryoTEM, and AFM. Spherical nanoparticles with average size 110-130 nm and zeta potential around -20 mV were identified for all EVs types. mEVs showed the highest levels of tetraspanins and integrins compared to nEVs and aEVs, suggesting superior adhesion and targeting to the inflamed tissues by mEVs. Strikingly, aEVs were preferentially taken up by neuronal cells in vitro, followed by mEVs and nEVs. Nevertheless, the brain accumulation levels of mEVs in a transgenic mouse model of Parkinson's disease were significantly higher than those of nEVs or aEVs. Therefore, mEVs were suggested as the most promising nanocarrier system for drug delivery to the brain.

Sialic acid-conjugate modified doxorubicin nanoplatform for treating neutrophil-related inflammation

Neutrophils, the most abundant leukocytes in human peripheral blood, are important effector cells that mediate the inflammatory response. During neutrophil dysfunction, excessive activation and uncontrolled infiltration are the core processes in the progression of inflammation-related diseases, including severe coronavirus disease-19 (COVID-19), sepsis, etc. Herein, we used sialic acid-modified liposomal doxorubicin (DOX-SAL) to selectively target inflammatory neutrophils in the peripheral blood and deliver DOX intracellularly, inducing neutrophil apoptosis, blocking neutrophil migration, and inhibiting the inflammatory response. Strong selectivity resulted from the specific affinity between SA and L-selectin, which is highly expressed on inflammatory neutrophil membranes. In inflammation models of acute lung inflammation/injury (ALI), sepsis, and rheumatoid arthritis (RA), DOX-SAL suppressed the inflammatory response, increased the survival of mice, and delayed disease progression, respectively. Moreover, DOX-SAL restored immune homeostasis in the body, without side effects. We have presented a targeted nanocarrier drug delivery system that can block the recruitment of inflammatory neutrophils, enabling specific inhibition of the core disease process and the potential to treat multiple diseases with a single drug. This represents a revolutionary treatment strategy for inflammatory diseases caused by inappropriate neutrophil activation.

Nanocelluloses: Sources, Pretreatment, Isolations, Modification, and Its Application as the Drug Carriers.

The ‘Back-to-nature’ concept has currently been adopted intensively in various industries, especially the pharmaceutical industry. In the past few decades, the overuse of synthetic chemicals has caused severe damage to the environment and ecosystem. One class of natural materials developed to substitute artificial chemicals in the pharmaceutical industries is the natural polymers, including cellulose and its derivatives. The development of nanocelluloses as nanocarriers in drug delivery systems has reached an advanced stage. Cellulose nanofiber (CNF), nanocrystal cellulose (NCC), and bacterial nanocellulose (BC) are the most common nanocellulose used as nanocarriers in drug delivery systems. Modification and functionalization using various processes and chemicals have been carried out to increase the adsorption and drug delivery performance of nanocellulose. Nanocellulose may be attached to the drug by physical interaction or chemical functionalization for covalent drug binding. Current development of nanocarrier formulations such as surfactant nanocellulose, ultra-lightweight porous materials, hydrogel, polyelectrolytes, and inorganic hybridizations has advanced to enable the construction of stimuli-responsive and specific recognition characteristics. Thus, an opportunity has emerged to develop a new generation of nanocellulose-based carriers that can modulate the drug conveyance for diverse drug characteristics. This review provides insights into selecting appropriate nanocellulose-based hybrid materials and the available modification routes to achieve satisfactory carrier performance and briefly discusses the essential criteria to achieve high-quality nanocellulose.

In vitro studies of Pluronic F127 coated magnetic silica nanocarriers for drug delivery system targeting liver cancer

In this study we synthesized and characterized iron oxide and mesoporous silica coated with Pluronic F127 nanocarriers using hydrothermal technique. The prepared nanoparticles were used as carriers for doxorubixin (DOX). The dynamic light scattering (DLS) of MNPs, MNPs-SiO2-F127-2% and MNPs-SiO2-F127-4% showed an average particle sizes of about 98.9, 127.6, and 136.2 nm, respectively. Furthermore, X-ray diffraction (XRD) analysis demonstrated that the as-prepared nanocarriers were crystalline, and the diffraction peak at 2θ = 35.44° in the XRD profiles of the nanocarriers corresponded to the (311) plane of Fe3O4. The peaks in the wavenumber range of 1630–1091 cm−1 observed in the Fourier-transform infrared (FTIR) spectra of the synthesized nanocarriers corresponded to the stretching vibration bands of Si–O bonds, demonstrating the successful coating of SiO2 on the surface of MNPs. The X-ray absorption near-edge spectra (XANES) of Fe atoms of MNPs, MNPs-SiO2-F127-2% and MNPs-SiO2-F127-4% revealed the presence of an absorbance peak (7112 eV) characteristic to the 1 s-to-3d transition. Cytotoxicity test confirmed that MNPs, MNPs-SiO2-F127-2% and MNPs-SiO2-F127-4% at different concentrations showed no significant cell toxicity toward the HEK293T and HepG2 cells. Additionally, MTT reduction results revealed that, after DOX was encapsulated in MNPs-SiO2-F127-2% and MNPs-SiO2-F127-4% nanocarriers, cell apoptosis was increased. In vitro analysis of the DOX release profile revealed that drug release was pH-dependent, and more DOX was released in acidic than in neutral microenvironments. In this study, we aimed to develop an advanced and innovative treatment against liver cancer using nanocarriers for DOX delivery. The developed drug delivery system or nanocarriers could improve the targeted DOX delivery for typical cancer treatment.

Evaluation of Low Molecular Weight Cross Linked Chitosan Nanoparticles, to Enhance the Bioavailability of 5-Flourouracil.

The present study aimed to formulate 5-fluorouracil loaded cross linked chitosan nanoparticles based on chemical cross-linking of low molecular weight chitosan with glutaraldehyde by reverse micelles technique as 5-FU is less hydrophobic, relatively potent, has a shorter half-life, is rapidly metabolized, less tolerated, and has low oral bioavailability; therefore, we aimed to formulate potential nanocarriers of 5-FU for efficient drug delivery to specific targeted areas of action, reduce oral toxicity, improve tolerability and therapeutic outcomes of 5-FU, in a restricted fashion to enhance the bioavailability of 5-FU. Nanoparticles were formulated by the reverse micelle method based on the chemical cross-linking of glutaraldehyde (25% aqueous solution) into a w/o emulsion in different ratios. LMWCH-NPs were characterized for post-formulation parameters by mean particle size, zeta potential, %age yield, loading/entrapment efficiency, Fourier transform infrared spectroscopy (FTIR), DSC/TGA, TEM, PXRD, drug release at pH 1.2, and pH 7.4. 5-FU loaded NPs showed a size range (198 nm-200 nm) and zeta potential (−39mV to −41mV), which ensured mechanical stability and increased retention time in blood vessels by the sustained release properties of biodegradable nanocarrier drug delivery systems. % age yield showed the range 92% to 96% while % LC ranged 2.0% to 3.4% and %EE ranged 40% to 43%. The TEM images showed spherical nanoparticles. FTIR revealed the compatibility between the drug and the cross-linked polymer. DSC/TGA ensured the thermal stability of the drug, while the solid-state stability of the drug-loaded cross-linked chitosan nanoparticles was evaluated by powder X-ray diffraction (PXRD) analysis. Drug release studies were performed using the dialysis bag technique at both pH (1.2 and 7.4) to mimic the gastrointestinal tract. Highly stable NPs displayed targeted release in phosphate buffer pH 7.4 at 37°C. Fickian diffusion was the predominant release with an R2 value of 0.9975-0.9973—and an N value 0.45-0.53. Prepared nanoparticles are inert, biodegradable, and biocompatible drug delivery systems for sustained release of 5-FU with maximum therapeutic efficacy and bioavailability.

Mechanistic insight into the binding of graphene oxide with human serum albumin: Multispectroscopic and molecular docking approach

Increasing manufacturing and use of nanoparticles in industrial and biomedical applications creates the necessity to understand the impact of the interaction of nanoparticles with biomacromolecules. In the present study, graphene oxide nanosheets (GONS) were synthesized using modified Hummer’s method and further characterized employing X-ray diffraction (XRD), UV, FTIR, and Raman spectroscopy. After characterization, the interaction of GONS with human serum albumin (HSA) was investigated to delineate the binding mechanism employing different kinds of spectroscopic techniques. Intrinsic fluorescence spectroscopy revealed that complex formation is taking place between HSA and GONS. Fluorescence-based binding studies suggested that GONS binds to HSA with a significant binding affinity, and the interaction is governed by dynamic quenching. The evaluation of enthalpy change (ΔH) and entropy change (ΔS) suggested that the HSA-GONS complex formation is driven by hydrogen bonding and van der Waals interaction and hence complexation process is seemingly specific. Structural transition in the microenvironment of HSA was monitored using synchronous fluorescence spectroscopy and three-dimensional fluorescence spectroscopy, which showed that GONS binding to HSA influences the microenvironment around tyrosine and tryptophan residues. Secondary structural alterations in HSA upon binding to GONS were measured using circular dichroism (CD) spectroscopy. Additionally, molecular docking provided an insight into the critical residues involved in HSA-GONS interaction and further validated our in vitro observations affirming interaction between GONS and HSA. The significance of this study is attributable to the fact that HSA and GONS can be used as nanocarriers in drug delivery systems.

Nanoemulsion as a Nano Carrier System in Drug Delivery: A Review

Nanoemulsions are colloidal dispersions having smaller globule size that ranges from 20-600 nm. They are clear transparent and kinetically stable formulations commonly available in the form of creams, shampoos, gels, sprays and aerosols. Nanoemulsions are nano carrier drug delivery system for the protection of drugs from severe environmental conditions like pH, oxidation and hydrolysis. Nanoemulsions are normally contains oil phase, aqueous phase, surfactants and co-surfactants. Different methods are employed for the preparations of nanoemulsions are high pressure homogenization, microfluidization, ultrasonication, spontaneous emulsifi- cation, membrane emulsification, phase inversion temperature and solvent displacement method. The stability of the nanoemulsions has the ability to protect the dosage unit microbial contamination physically and chemically. They can be administered via nasal route, orally, topically, transdermally and also used as prophylactically in bio-terrorism attack and as diagnostic agent. They can be used for the delivery of various types of drugs like vaccines, DNA encoded drugs, antibiotics and vitamins. Various patents on nanoemulsions are also discussed. Nanoemulsions are nano carrier system with safe and effective delivery of lipophilic and hydrophilic drug and also used in targeting.

Engineering of dendritic mesoporous silica nanoparticles for efficient delivery of water-insoluble paclitaxel in cancer therapy

The efficacy of hydrophobic chemotherapy drugs in cancer treatment is often hampered by their poor solubility in the physiological environment, which causes their low delivery efficiency in the body. This manuscript develops an intelligent nanocarrier (~100 nm) drug delivery system that can highly load a water-insoluble drug, and possesses desirable tumor-targeting properties for cancer therapy. In this system, highly porous silica nanoparticles (pore volume ~ 1.4 cm3 g−1) with a dendritic pore structure (denoted as DMSN) are applied as a matrix for drug loading. A facile, vacuum rotary evaporation-mediated casting method is applied to quantitatively load a high content of a hydrophobic drug (i.e., paclitaxel) in the DMSN matrix. A thiol-modified poly(methacrylic acid) (denoted as PMAsh) shell is then assembled and crosslinked via disulfide bonds on the particle surface to improve the dispersibility of the particles in an aqueous environment. After functionalization of the PMAsh shell with the targeting ligand transferrin (Tf), the nanocarriers exhibit accumulation ability on tumor cells, both in vitro and in vivo. Combining the fascinating properties of high drug-loading, excellent colloidal stability, low cytotoxicity, targeting ability and glutathione-responsive PMAsh shell deconstruction properties, the nanocarriers described here hold great promise for the efficient delivery of hydrophobic drugs and tumor treatment.

Nanocarrier Drug Delivery Systems for Colorectal Cancer

Nanocarrier Drug Delivery Systems for Colorectal Cancer